首页|Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)

Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)

扫码查看
原文链接
  • NSTL
  • Lippincott Williams & Wilkins
The objective of this study was to propose prognostic factors and optimal treatment strategies by analyzing the clinicopathological features and programmed death-ligand 1 (PD-L1) expression. We analyzed 31 patients diagnosed with uterine or ovarian melanoma between 1997 and 2017 in the Kansai Clinical Oncology Group/Intergroup. Twenty-four and seven patients with cervical and ovarian melanomas were included, respectively. Immune checkpoint inhibitors were used in seven patients, and the objective response rate was 40%. Notably, two patients with objective responses had a high PD-L1 expression. Ten and four patients with cervical and ovarian melanomas, respectively, had high PD-L1 immunohistochemical expressions. Multivariate analysis revealed that tumor stage was an independent prognostic factor for progression-free survival in patients with cervical melanomas. In patients with ovarian melanomas, the 1-year cumulative progression-free and overall survival rates were 0 and 29%, respectively. Kaplan-Meier analyses revealed that age <60 years was associated with poorer progression-free and overall survivals in patients with ovarian melanomas. In patients with cervical melanomas, the 1-, 3-, and 5-year cumulative overall survival rates were 53, 32, and 16%, respectively. Histological atypia was associated with a poorer progression-free survival, but there was no difference in survival between patients who underwent radical hysterectomy and those who did not. The present study is a large cohort study of uterine and ovarian melanomas, which are aggressive tumors with a significantly poor prognosis, even after standard surgery and adjuvant therapy. The use of immune checkpoint inhibitors is a promising and effective treatment option.

cervixmalignant melanomamucosal melanomaovaryprogrammed death-ligand 1prognosissurvivalteratomatreatmentuterusMALIGNANT-MELANOMAMUCOSALIPILIMUMABNIVOLUMABBRAF

Kobara, Hisanori、Matsuura, Motoki、Tokuyama, Osamu、Yamawaki, Takaharu、Wakahashi, Senn、Noguchi, Tomoko、Mizuno, Kaoruko、Shitsukawa, Keiji、Onohara, Yoshimasa、Nakabori, Takashi、Miyasaka, Aki、Nakao, Takehiro、Matsunaga, Tatsuya、Kunimi, Yusuke、Sakurai, Manabu、Uchiyama, Aya、Itoh, Ryoji、Ohike, Nobuyuki、Hirakawa, Takashi、Watanabe, Tadashi、Nishino, Koji、Motohashi, Takashi、Ito, Kimihiko、Yano, Mitsutake、Nasu, Kaei、Yasuda, Masanori、Katoh, Tomomi、Kagabu, Masahiro

展开 >

Dept Obstet & Gynecol,Shinshu Univ

Sch Med,Sapporo Med Univ

Dept Obstet & Gynecol,Osaka City Gen Hosp

Dept Obstet & Gynecol,Ise Red Cross Hosp

Dept Obstet & Gynecol,Kobe Univ

Dept Obstet & Gynecol,Wakayama Med Univ

Dept Obstet & Gynecol,Shizuoka City Shizuoka Hosp

Dept Obstet & Gynecol,Tokushima Prefecture Naruto Hosp

Dept Obstet & Gynecol,Tottori Prefectural Kousei Hosp

Dept Obstet & Gynecol,Kurashiki Cent Hosp

Fac Med,Univ Tokyo

Dept Gynecol,Nihon Univ

Dept Obstet & Gynecol,Yokohama City Univ

Dept Obstet & Gynecol,Kochi Hlth Sci Ctr

Fac Med,Univ Tsukuba

Dept Gynecol,Kanagawa Canc Ctr

Dept Obstet & Gynecol,Kusatsu Gen Hosp

Fujigaoka Hosp,Showa Univ

Dept Obstet & Gynecol,Gunma Univ

Dept Obstet & Gynecol,Tohoku Med & Pharmaceut Univ

Dept Obstet & Gynecol,Niigata Univ

Dept Obstet & Gynecol,Tokyo Womens Med Univ

Dept Obstet & Gynecol,Kansai Rosai Hosp

Fac Med,Oita Univ

Dept Pathol,Saitama Med Univ

Sch Med,Iwate Med Univ

展开 >

2022

10.1097/CMR.0000000000000811

Melanoma research

Melanoma research

SCI
ISSN：0960-8931
年,卷(期)：2022.32(3)
  • 1
  • 22